Desentum Oy

Teknologian Tutkimuskeskus Vtt Oy

Politecnico Di Milano

Teknologian Tutkimuskeskus Vtt

Juha Rouvinen

Kristiina Takkinen

Merja Niemi

Marja-Leena Laukkanen

Hans Söderlund

Sirpa Jylhä

Janne Jänis

Hans Soederlund

Sirpa Jylhae

Pierangelo Metrangolo

Henri Arola

Tarja Nevanen

Antti Tullila

Soili Mäkinen-Kiljunen

Heidi Holkeri

Tari Haahtela

Tarja Parkkinen

Jaana Haka

Soili Maekinen-Kiljunen

Hans Soderlund

Janne Janis

Sirpa Jylha

The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.

Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy

The present invention relates to the fields of antibodies, antigen binding fragments and immunodiagnostics. Specifically, the invention relates to a recombinant anti-body or antigen binding fragment for binding thyroid hormone T4 (thyroxine) and halogenated bisphenol A. Also, the present invention relates to an isolated nucleic acid molecule comprising a nucleotide sequence that encodes the recombinant antibody or antigen binding fragment of the present invention, as well as an ex-pression vector and host cell comprising the nucleic acid molecule of the present invention. Still, the present invention relates to a method of producing a recombi-nant antibody or antigen binding fragment for binding T4 thyroid hormone and hal-ogenated bisphenol A, a test kit and an immunoassay comprising the recombinant antibody or antigen binding fragment of the present invention, and a method for determining T4 thyroid hormone and/or halogenated bisphenol A levels in a sam-ple of a subject. Still further, the present invention relates to a method of treating a sample, e.g. an immunoaffinity-based sample preparation method for enrich-ment of the halogenated bisphenol A from a sample.

Anti-thyroid hormone (T4) recombinant antibody or antigen binding fragment

The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy.

Hypoallergen

The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in &#x3b2;-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics and immunotherapy.

Allergen-binding IgE monoclonal antibodies and method for preparing hypoallergens

The present invention is related to field of allergic (hypersensitivity) diseases and provides a method for producing modified allergenic polypeptides for use in immunotherapies. In the method of the invention, said allergenic polypeptides are modified so that they are not capable to form transient dimers. The invention also provides modified &#x3b2;-lactoglobulins for use in immunotherapy of milk allergy.

Modified beta-lactoglobulins for immunotherapy of milk allergy

Growing community of inventors

Joensuu, Finland

Juha Rouvinen